Fosun 复星’s Post

🌍 Expanding Horizons: Big Pharma’s Strategic Shift to Emerging Markets 🌍 As growth slows in traditional markets, Big Pharma is focusing on emerging economies like India, China, and Brazil — where opportunities for innovation and accessibility are reshaping the industry. 📈 In our latest article, we dive into: ✅ Why major pharmaceutical companies are investing in these markets. ✅ The innovative strategies companies like Novartis and Bristol Myers Squibb are using to enhance access and affordability. ✅ The unique challenges they face, from regulatory hurdles to ensuring equitable healthcare access. At Euro-American Worldwide Logistics, we’re playing a pivotal role in helping these companies navigate the complexities of emerging markets with tailored logistics solutions to ensure critical medicines reach patients reliably and efficiently. Read the full article on our website and discover how global logistics is fueling Big Pharma’s next frontier. 👉 https://lnkd.in/dYMidT9M #PharmaExpansion #EmergingMarkets #GlobalLogistics #PharmaceuticalInnovation #LifeSciences

IMEXPHARM CONTINUES TO BE NAMED AMONG THE TOP 50 BEST-LISTED COMPANIES ✨ On June 17th, 2024, Imexpharm Pharmaceutical Joint Stock Company was once again announced by Forbes Vietnam as one of the "Top 50 Listed Companies" in 2024. ✨To be included in the Top 50 Listed Companies list in 2024, listed companies on the Ho Chi Minh Stock Exchange (HSX) and the Hanoi Stock Exchange (HNX) went through several evaluation steps. In the preliminary round, companies needed to meet the following criteria: having profits in 2023, minimum revenue and market capitalization of 500 billion Vietnamese dong. In the next round, companies were assessed quantitatively based on five criteria: compound growth rates of revenue, profit, return on equity (ROE), return on capital (ROC), and growth of earnings per share (EPS) during the 2019-2023 period. Forbes Vietnam then conducted qualitative research to evaluate the sustainable development of the companies, including their market position, profit sources, quality of corporate governance, and industry prospects. The list was supported by quantitative calculations from the Ho Chi Minh City Securities Company (HSC). The market capitalization was finalized on May 30, 2024. The financial reporting used for the calculation was the audited consolidated financial statements for the year 2023. ✨This is the third consecutive time that Imexpharm has been included in the Top 50 list, with revenue and profit figures of 1,994 billion and 299 billion Vietnamese dong, respectively. It is believed that with its investment strategy in quality and sustainable development, Imexpharm will achieve even more success in the future as it continues to contribute to comprehensive healthcare in Vietnam. #Vungbuoctienphong #ProudofImexpharm #Chatluonghangdautieuchuanchauau

📈 Global M&A activity reveals significant regional differences! While countries like Italy (+100%), the UK (+84%), and Africa (+70%) are seeing strong growth in transaction volumes, other regions such as China (-20%) and Benelux (-31%) show declines. Particularly exciting is the rise in M&A within the #Pharma and #Biotech sectors, where strategic partnerships and acquisitions are playing an increasingly pivotal role. 🌍 As a specialized Consultant focused on Business Development roles in Pharma and Biotech, I'm witnessing firsthand how critical these activities are becoming for driving innovation and market expansion. The demand for strategic thinkers and leaders who can identify and execute high-impact partnerships is only growing. ❗ Exciting times ahead for those of us shaping the future of healthcare! Source: Mergermarket #pharma #BioTech #BusinessDevelopment #MergersAcquisitions #skillsalliance

🌍 The first day of the 2nd Strategic Project, Program and Portfolio Management Conference for Pharmaceuticals in Mumbai kicked off with an insightful keynote session on Market Entry Strategies led by Sandeep Joshi, Head of Emerging Markets at USV PRIVATE LIMITED Participants learned about the internationalization of firms' value chains and the key criteria for deciding which market to enter. 🤔💡Which of the mentioned risks do you believe should be prioritized? Share your thoughts in the comments! #PharmaConference #MarketEntryStrategies

How will China's innovative healthcare industry navigate the "capital winter" and seize global opportunities? 🇨🇳 ✈️🌍 I had the pleasure of sharing my thoughts with Ji Yuanyuan and Han Liming from 21st Century Business Herald, leading business publication in Shanghai, on the current challenges and future prospects of China’s biopharma sector. From the tightening IPO market to evolving global collaborations, the industry is at a critical turning point. Read more to discover why I believe this "winter" could soon give way to spring—and which companies will emerge stronger than ever. Check out the full article here! 👇https://lnkd.in/gNDJu98M Read the original Chinese article here: https://lnkd.in/gztHDbpt #GoGlobal #CapitalWinter #HealthcareInnovation

Happy Friday from RJM! 🎉 As we wrap up the week, the latest insights from BMI reveal that nearshoring is set to redefine the supply chain landscape, particularly in the pharmaceutical sector. 🌍💊 With Asia-Pacific turning protectionist amidst economic challenges, Southeast Asia is emerging as a key player, offering exciting opportunities for growth. Countries like Vietnam and Indonesia are poised to benefit as pharmaceutical companies look to diversify supply chains and reduce dependency on single markets. 📦✨ The projection? Pharmaceutical sales in the region are expected to skyrocket from $29.2 billion in 2023 to $38.2 billion by 2028! 📊 The shift away from globalization is pushing industries to rethink their strategies, and nearshoring is becoming a go-to approach for enhancing resilience and ensuring secure, reliable supply chains. 🛠️🌱 What does this mean for businesses? It’s time to embrace the opportunities nearshoring presents—especially in Southeast Asia, where favorable labor conditions and growing infrastructure make it a prime destination for investment. This evolving landscape is transforming the future of pharmaceuticals, and we at RJM are keeping a close eye on these developments. 👀💼 Let’s start thinking ahead—how will your business adapt to these shifting dynamics? #SupplyChain #Nearshoring #Pharmaceuticals #SoutheastAsia #Globalization #EconomicGrowth #RJM #FridayInsights

𝗟𝗘𝗧'𝗦 𝗧𝗔𝗞𝗘 𝗔 𝗖𝗟𝗢𝗦𝗘𝗥 𝗟𝗢𝗢𝗞 𝗔𝗧 𝗜𝗠𝗘𝗫𝗣𝗛𝗔𝗥𝗠'𝗦 𝗕𝗨𝗦𝗜𝗡𝗘𝗦𝗦 𝗣𝗘𝗥𝗙𝗢𝗥𝗠𝗔𝗡𝗖𝗘 𝗜𝗡 𝗧𝗛𝗘 𝗙𝗜𝗥𝗦𝗧 𝟵 𝗠𝗢𝗡𝗧𝗛𝗦 𝗢𝗙 𝟮𝟬𝟮𝟰 Despite a complex industry landscape with a lot of challenges, Imexpharm has achieved solid growth: 💰 𝗡𝗘𝗧 𝗥𝗘𝗩𝗘𝗡𝗨𝗘 ●     First 9 months: 1️⃣.5️⃣5️⃣3️⃣ billion VND, up 12% year-on-year, reaching 66% of the annual target. ●     Q3: 545 billion VND, up 17% from the same period last year, boosted by a strong position in the ETC channel. ●     September alone: 209 billion VND, marking an 18% increase compared to August and 28% year-on-year. 💊 𝗣𝗥𝗢𝗙𝗜𝗧 𝗕𝗘𝗙𝗢𝗥𝗘 𝗧𝗔𝗫 𝗔𝗡𝗗 𝗘𝗕𝗜𝗧𝗗𝗔 ●     First 9 months: Achieved 252 billion VND in profit before tax and 334 billion VND in EBITDA, down 12% and 4% year-on-year, respectively. ●     Q3: EBITDA margin rose to 2️⃣2️⃣% thanks to strong revenue growth at IMP4 and effective cost management. 🏢 Cat Khanh Pharmaceutical Factory Complex Project in Dong Thap: Expected to be completed in late 2028, covering 25,000 m² with a projected investment of 1️⃣.4️⃣9️⃣5️⃣ billion VND. ✨ Moving into Q4, Imexpharm is confident that its performance is propelling the Company towards a final result approaching the 2024 targets set during its Shareholder Meeting at the beginning of the year. It regularly reviews its progress towards these targets as part of its internal evaluation process, and will provide any necessary updates through the rest of the year as appropriate and in line with its commitment to timely and transparent communications. 🧡 Imexpharm extends its sincere appreciation to its customers, shareholders and partners for their continued support and trust throughout its growth journey, and looks forward to the future with confidence. #IMP #Imexpharm #EUGMP

Japan’s Mitsui & Co., Ltd. and ROHTO Pharmaceutical Co., Ltd. have acquired an 86% stake in Eu Yan Sang International for S$687 million in cash. Tower Capital Asia announced that its investment holding company, Righteous Crane Holding (RCH), along with Temasek Holdings subsidiary Blanca Investments and some members of the Eu family, are selling their combined stake in the company. The deal values Eu Yan Sang at about S$800 million. Two members of the Eu Family will retain about 10% of their interest in the company and become shareholders of the consortium to provide guidance. Eu Yan Sang chairman Richard Eu expressed gratitude to Tower Capital Asia and Temasek for transforming Eu Yan Sang into a leading natural health and wellness enterprise and welcomed the company’s new shareholders. The transaction is subject to regulatory approvals and is expected to close by June 2024. #PrivateEquity #Merger #Acquistion #TraditionalChineseMedicine #Growth #Innovation #Health #Business #Finance #Japan #Singapore #HongKong #Malaysia I The Business Times l SPH Media I Jun Yuan Yong

𝐌&𝐀 𝐁𝐨𝐨𝐦 𝐨𝐧 𝐭𝐡𝐞 𝐇𝐨𝐫𝐢𝐳𝐨𝐧 𝐟𝐨𝐫 𝐌𝐄𝐍𝐀 𝐏𝐡𝐚𝐫𝐦𝐚 The Middle East and North Africa (MENA) pharmaceutical market is experiencing explosive growth, exceeding 7-9% annually and reaching a market size of over $40 billion! This surge is attracting major players and setting the stage for a surge in mergers and acquisitions (M&A) activity. 𝐇𝐞𝐫𝐞'𝐬 𝐰𝐡𝐲 𝐌𝐄𝐍𝐀 𝐩𝐡𝐚𝐫𝐦𝐚 𝐢𝐬 𝐫𝐢𝐩𝐞 𝐟𝐨𝐫 𝐌&𝐀: 𝙈𝙖𝙧𝙠𝙚𝙩 𝙈𝙖𝙩𝙪𝙧𝙖𝙩𝙞𝙤𝙣: As the market matures, companies will seek to consolidate, expand geographically, and access new technologies through M&A. 𝙎𝙩𝙧𝙖𝙩𝙚𝙜𝙞𝙘 𝙊𝙥𝙥𝙤𝙧𝙩𝙪𝙣𝙞𝙩𝙞𝙚𝙨: M&A can be a game-changer, allowing companies to: A) Strengthen Market Position (e.g., Hikma acquiring Boehringer Ingelheim's MENA consumer care business in 2021 for $820 million) B) Gain a Foothold in New Markets (e.g., Sanofi acquiring TheraVitae in 2020 for $500 million to enter the Saudi biopharma market) C) Create Regional Powerhouses (e.g., the 2019 merger of IPharma and Pharco) Fasten your seatbelts! We can expect a rapid increase in M&A activity in the coming years. ️ My question is: 𝙒𝙝𝙞𝙘𝙝 𝙈𝙀𝙉𝘼 𝙥𝙝𝙖𝙧𝙢𝙖 𝙘𝙤𝙢𝙥𝙖𝙣𝙞𝙚𝙨 𝙙𝙤 𝙮𝙤𝙪 𝙩𝙝𝙞𝙣𝙠 𝙨𝙝𝙤𝙪𝙡𝙙 𝙗𝙚 𝙖𝙘𝙩𝙞𝙫𝙚𝙡𝙮 𝙨𝙘𝙧𝙚𝙚𝙣𝙞𝙣𝙜 𝙛𝙤𝙧 𝙖𝙘𝙦𝙪𝙞𝙨𝙞𝙩𝙞𝙤𝙣 𝙩𝙖𝙧𝙜𝙚𝙩𝙨? #MENApharma #PharmaM&A #MarketGrowth #Investment #Networking P.S. If you're interested in learning more about MENA pharma's M&A landscape, feel free to connect and chat!

SURVIVAL OF THE FITTEST... It is a well known process that results in the evolution of organisms to acquire better design enabling them fitting to the environment. In Egypt there are almost 191 manufacturing pharmaceutical companies amongst them maybe 90% are Egyptian organizations all of them supply 'ME TOO PRODUCTS' with difficulty in distinguishing one another. With the existing pressing economy the game expected to be changed to reduce the operating cost through: - Mergers and acquisitions to form giant organizations -  Transformation of the way of working namely evolution of medical promotion exploring Alternative Selling Models e g. digital marketing initiatives   Successful organization don't wait for change, don't accept to be only part of the change, yet they drive it forward with their strategic foreseen and this represents a key  difference between WINNERS and LOSERS....